B Narasimhulu Naidu

This inventor holds 55 USPTO granted patents and 22 published patent applications and 20 EPO patents, primarily in HIV Inhibitors (CPC class C07D). Top assignees: Bristol-Myers Squibb Compnay, Viiv Healthcare UK (No.5) Limited. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: B Narasimhulu Naidu. Retrieved from https://idiyas.com/inventor/b-narasimhulu-naidu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 55 (Patent Applications = 22)

% Patents Active = 50.9

EPO Patents = 20 (Patent Applications = 50)

Average Co-Inventor Count = 3.9

ph-index = 10

Forward Citations = 213(Granted Patents)

Forward Citations (Not Self Cited) = 158(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Durham, CA (US) (2015)
Durham, CO (US) (2016)
Durham, CT (US) (2005 - 2017)
Wallingford, CT (US) (2017 - 2020)
Branford, CT (US) (2021 - 2022)

Company Filing History:

31 out of 3,745

Bristol-Myers Squibb Compnay

patents

24 out of 45

Viiv Healthcare UK (No.5) Limited

patents

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

HIV Integrase Inhibitors

Pyridine Derivatives

Macrocycles

Imidazopyridine

Pyrazolopyrimidine

Acetic Acid Derivatives

Human Immunodeficiency Virus

Inhibitors

Benzothiazole

Tricyclic Aryl

Tetrahydroisoquinoline

55 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12594276 - Inhibitors of human immunodeficiency virus replication (2026-04-07),

2. 11505543 - 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication (2022-11-22),

3. 10954252 - Inhibitors of human immunodeficiency virus replication (2021-03-23),

4. 10577353 - 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication (2020-03-03),

5. 10407410 - Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication (2019-09-10),

6. 10351546 - Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication (2019-07-16),

7. 10221156 - Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication (2019-03-05),

8. 10214516 - 5-(N-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication (2019-02-26),

9. 10189816 - Substituted pyridines as inhibitors of human immunodeficiency virus replication (2019-01-29),

10. 10138253 - Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication (2018-11-27),

11. 10125148 - Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication (2018-11-13),

12. 10106504 - Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication (2018-10-23),

13. 10065953 - Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication (2018-09-04),

14. 9944656 - Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication (2018-04-17),

15. 9938271 - Inhibitors of human immunodeficiency virus replication (2018-04-10),

Title: B Narasimhulu Naidu: Innovator in HIV Research

Introduction

B Narasimhulu Naidu is a prominent inventor based in Durham, Connecticut, with an impressive portfolio of 54 patents. His contributions to the field of pharmaceutical chemistry, particularly in the area of human immunodeficiency virus (HIV) research, have made substantial impacts on the scientific community and public health.

Latest Patents

One of Naidu's latest patents focuses on "4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication." This patent includes compounds of Formula I, which comprise pharmaceutically acceptable salts and methods for treating HIV infection. Another notable patent shares a similar title, emphasizing the significance of these compounds in combating HIV replication. His research in this area is critical for developing effective treatments against this global health issue.

Career Highlights

Naidu has had a distinguished career, working with reputable companies in the pharmaceutical industry. He has contributed his expertise to Bristol Myers Squibb Company and ViiV Healthcare UK (No.5) Limited, where he has played a vital role in HIV research and the development of new therapies. His focus on innovative solutions showcases his commitment to addressing complex health challenges.

Collaborations

Throughout his career, Naidu has collaborated with numerous professionals, enhancing the innovation process. Notable coworkers include Manoj Patel and Kevin M Peese, with whom he has shared his insights and expertise, fostering an environment of creativity and scientific advancement.

Conclusion

B Narasimhulu Naidu's extensive patent portfolio and his work in HIV research demonstrate his invaluable contributions to science and innovation. His dedication to discovering new pharmaceutical compounds continues to influence the fight against HIV, making him a key figure in the industry. As he progresses in his career, Naidu's future endeavors are anticipated with great interest by his peers and the scientific community.

Profile summary based on public USPTO records.